Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2022: Panel discussion on bladder preservation

Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller

ASCO 2022: Panel discussion on bladder preservation ( Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller )

ASCO 2022: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Pembrolizumab demonstrates clinically meaningful improvement in distant...

Dr Georgina Long - The University of Sydney, Sydney, Australia

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford

ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA...

Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer...

Dr Pamela Kunz - Yale Cancer Center, New Haven, USA

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal...

Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer